3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
147
Melanoma
122
Breast Neoplasms
98
Squamous Cell Carcinoma of Head and Neck
96
Triple Negative Breast Neoplasms
85
Lung Neoplasms
64
Neoplasm Metastasis
53
Carcinoma, Renal Cell
49
Neoplasms
46
Head and Neck Neoplasms
46
Colorectal Neoplasms
41
Ovarian Neoplasms
38
Carcinoma, Transitional Cell
37
Carcinoma, Hepatocellular
36
Pancreatic Neoplasms
35
Urinary Bladder Neoplasms
34
Recurrence
33
Stomach Neoplasms
32
Glioblastoma
30
Brain Neoplasms
28
Sarcoma
26
Endometrial Neoplasms
25
Prostatic Neoplasms
23
Hodgkin Disease
22
Uterine Cervical Neoplasms
19
Fallopian Tube Neoplasms
19
Carcinoma, Squamous Cell
19
Esophageal Squamous Cell Carcinoma
17
Adenocarcinoma
17
Multiple Myeloma
16
Interventions
Acupuncture Therapy
10
Exercise
6
Cryotherapy
6
Paclitaxel
5
Glutamine
4
Surveys and Questionnaires
3
Duloxetine Hydrochloride
3
Dexamethasone
3
Bortezomib
3
Acetylcysteine
3
Thioctic Acid
2
Tablets
2
Sodium Chloride
2
Saline Solution
2
Physical Therapy Modalities
2
Low-Level Light Therapy
2
Fish Oils
2
Fatty Acids, Omega-3
2
ziconotide
1
pembrolizumab
1
nicotinamide-beta-riboside
1
glutamic acid diethyl ester
1
enfortumab vedotin
1
Yoga
1
XELOX
1
Vitamin D
1
Vitamin B Complex
1
Vitamin B 6
1
Vitamin B 12
1
Ultrasonic Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Peripheral Nervous System Diseases
×
pembrolizumab
×
Clear all
NCT07629700
2026-06-05
ENDEAVOR
University of Florence
Phase NA
Not yet recruiting
40 enrolled